AzTrials
AzTrials

Living Donor Liver TransplantationLRLDLTNCT07329296

The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study

An observational study of Living Donor Liver Transplantation, run by Erasmus Medical Center at 1 site in Netherlands.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Rationale: Living donor liver transplantation (LDLT) offers a promising solution to the organ shortage. During living liver donation, a substantial portion of the donor's liver is resected. Fortunately, the liver has a remarkable capacity to regenerate. However, liver regeneration varies among individuals. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Living Donor Liver Transplantation
What is being tested?
Living liver donation
Type of treatment
Surgery or procedure
How many people
90 participants
Where
1 siteNetherlands
Study dates
1 Feb 2026to 30 Sep 2027
How long will I take part?
1 Year
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: The population consists of adult living liver donors at the Erasmus MC.

Who may be able to join

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Living liver donation between May 2004 and June 2026
  • Written informed consent
  • In order to be eligible for LDLT, a subject needed to meet all of the following criteria:
  • 18-60 years old
  • Physical and mental well-being
  • Body Mass Index (BMI) <33 kg/m2
  • No active drugs or other substances use

Who cannot join

  • There are no exclusion criteria for this study.
  • Absolute exclusion criteria
  • Medical conditions (for instance heart disease and bleeding or clotting disorders)
  • History of liver disease
  • Previous/active malaria infection
  • Financial incentive or indications of pressure
Show all 16Show fewer
  • Unable to cooperate with designated long-term follow-up
  • Severe psychiatric disease or psychological instability
  • Active alcoholism or frequent heavy alcohol use or drugs use/abuse
  • Unable to give informed consent
  • History of dementia or other neurological degenerative disorders
  • Persons with rabies or persons bitten in the past 6 months by an animal and that are treated as if the animal is rabid
  • Persons with syphilis
  • Human immunodeficiency virus-positive persons. Relative exclusion criteria
  • BMI >33 kg/m2
  • Smoking

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Netherlands1 site
  • Erasmus Medical Center

    Rotterdam, South Holland, 3015 GD

Other trials in Netherlands

About this study

Rationale: Living donor liver transplantation (LDLT) offers a promising solution to the organ shortage. During living liver donation, a substantial portion of the donor's liver is resected. Fortunately, the liver has a remarkable capacity to regenerate. However, liver regeneration varies among individuals. Previous studies have identified several clinical factors as potential predictors of regenerative capacity. Nevertheless, these studies are outdated and do not reflect current clinical practice or recent advancements. This study aims to investigate the regenerative capacity of the donor liver following LDLT and identify its clinical predictors. It is hypothesized that the liver regenerates to the original size.

Objectives: The main objective of this study is to evaluate the regenerative capacity of the donor liver following LDLT. The secondary objective is to identify clinical predictors of the regenerative capacity of the donor liver following LDLT.

Read more

Study type: This is an ambidirectional, single-center cohort study using medical records.

Study population: The population consists of adult living liver donors aged 18-60 years at the Erasmus MC who donate(d) between May 2004 and June 2026 and gave written informed consent.

Methods: General, graft weight and liver volumetry data will be extracted from HiX. The study coordinator will register his findings and analyze them. The paired samples t-test will be used to test for differences in mean remnant liver volume and liver volume 12 months post-donation. In addition, subgroup analyses will be performed for sex, age, weight, type of liver graft donation, anatomical variants, liver steatosis, and donor complications. Multiple linear regression analysis will be performed for sex, age, BMI, donor length of stay, remnant liver volume and percentage, and type of liver graft donation.

Read the detailed description

Research methods: General and graft weight data will be extracted from HiX. Additionally, liver volume pre-donation (VPRD) and 12 months post-donation (V12M) from CT- or MRI-volumetry will be extracted from HiX. The study coordinator will register his findings in Castor.

Analysis: Normality will be tested using the Shapiro-Wilk test. Homogeneity of variances will be tested using the F-test. A QQ plot will be used to check for outliers. For the baseline donor characteristics, mean (standard deviation (SD)) age, weight, height, BMI, and the percentage of females and related donations, will be calculated. A table of these parameters will be made.

The surgical outcomes OR time, blood loss, donor LOS, and Clavien-Dindo ≥III complications will be described and mean (SD) of these parameters will be calculated. A table of these parameters will be made.

The mean (SD) remnant liver volume (RLV) and V12M will be calculated. The regenerative capacity will be calculated by the formula: regenerative capacity = V12M/RLV * 100(%). For the mean regenerative capacity, the average of all donors' regenerative capacities will be taken. A table showing the means (SD) and min-max of RLV, V12M, and the regenerative capacities will be made. The distribution of regenerative capacities will be shown in a bar chart. The paired samples t-test will be used to test for differences in mean RLV and liver volume 12 months post-donation (V12M). In addition, subgroup analyses will be performed for sex, age (<40 vs ≥40 years), weight (<70 vs ≥70 kg), type of liver graft donation (right vs left lobe), anatomical variants, liver steatosis, and donor complications using the unpaired samples t-test, Welch's t-test, or Mann-Whitney test. Multiple linear regression analysis will be performed for the following 7 potential predictors of regenerative capacity: sex, age, BMI, donor LOS, remnant liver volume and percentage, and type of liver graft donation (right vs left lobe). Variance inflation factor (VIF) will be used to test for multicollinearity. Statistical analyses will be carried out using RStudio 2024.09.1, GraphPad Prism 9.5.0, and Microsoft Excel version 16.90.2. P<0.05 indicates statistical significance.

Recruitment and informed consent procedures: The transplant coordinator and/or transplant surgeon will inform participants about the study and will ask their written informed consent. Living liver donors are followed up annually for life. The participants will be informed during a follow-up consult. All donors who are, for whatever reason, not visiting the Erasmus MC anymore for follow-up are contacted by phone. If the donor considers participating, a Patient Information Form (PIF) will be sent by mail. The donors can return the signed PIF through mail. Donors can withdraw their informed consent at any time and for any reason if they wish to do so without any consequences. They can withdraw through phone, mail, or in person.

Privacy protection: Subject's privacy is protected by using coded data. In the database subjects are referred to as numbers. These numbers are chosen at random. Which number belongs to which subject is registered in a key table with a password. This password is only known by the principal investigator and the research team. The database in which the data is stored (Castor), meets the requirements set for data security. The handling of personal data is in compliance with the Dutch Data Protection Act (in Dutch: 'Algemene Verordening Gegevensbescherming (AVG)). Only the code number will be used for study documentation, progress reports, and research publications.

Being tested
Living liver donation
Keywords
Liver Transplantation, Living Donor, Magnetic Resonance Imaging, Liver Regeneration

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Living liver donationProcedure or surgery

    Adults who underwent living liver donation.

Study groups in NCT07329296
Study groupRoleWhat they receive
Living liver donorsThe population consists of adult living liver donors at the Erasmus MC.
Receives: Procedure: Living liver donation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Liver regeneration

    The primary outcomes are remnant liver volume (RLV), assessed by subtracting the graft weight from the volume pre-donation, and the liver volume 12 months post-donation. Liver volumes are assessed with CT- or MRI-volumetry.

    Measured: Preoperative during screening for living liver donation and 1 year post-donation.

Secondary outcomes (1)
  1. Predictors

    Secondary outcomes are clinical parameters possibly correlated with the regenerative capacity of the donor liver after LDLT. The following clinical predictors are studied: gender, age, BMI, donor length of stay, remnant liver volume and percentage, type of liver graft donation (right vs left lobe), anatomical variants, and liver steatosis.

    Measured: Preoperative during screening for living liver donation and during follow-up until 1 year post-donation.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jan 2026
  2. Study start1 Feb 2026 (estimated)
  3. Primary completion1 Jun 2027 (estimated)
  4. Study completion30 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
90 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT07329296
Sponsor's protocol ID
MEC-2025-0362
Acronym
LRLDLT
Status last verified
Dec 2025
First submitted
29 Dec 2025
Last updated
9 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Study protocol, documentation, data management plan, data analysis plan, script to assess data, scripts to analyse data, scripts to generate tables and figures in the publication.

Publications

  • Pomfret EA, Pomposelli JJ, Gordon FD, Erbay N, Lyn Price L, Lewis WD, Jenkins RL. Liver regeneration and surgical outcome in donors of right-lobe liver grafts. Transplantation. 2003 Jul 15;76(1):5-10. doi: 10.1097/01.TP.0000079064.08263.8E.

    PubMed 12865779
  • Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007 Nov;213(2):286-300. doi: 10.1002/jcp.21172.

    PubMed 17559071
  • Yim SH, Kim DG, Kang M, Koh HH, Choi MC, Min EK, Lee JG, Kim MS, Joo DJ. Survival benefit of living-donor liver transplantation in patients with a model for end-stage liver disease over 30 in a region with severe organ shortage: a retrospective cohort study. Int J Surg. 2023 Nov 1;109(11):3459-3466. doi: 10.1097/JS9.0000000000000634.

    PubMed 37565633

Questions about this trial

What is this clinical trial studying?

An observational study of Living Donor Liver Transplantation, run by Erasmus Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Liver regeneration (time frame: Preoperative during screening for living liver donation and 1 year post-donation.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07329296, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in